Valuation

ICLRICON plc

StockNasdaqIrelandHealth careEU retail investors: available

−1.4% today · +29.8% over a year

4/10 A 1–10 summary of how an instrument compares with similar ones (same sector and region) by published rules. It describes today's data; it is not a price forecast. More in the glossary → «Balanced» — higher than 39% of the instruments we score

Stability: among the weakest; priced lower than most peers. No dividend.

ICON plc (ICLR) valuation against sector peers: P/E 34.2 (sector median 25.7), P/B 1.7, EV/EBIT 25.0, free-cash-flow yield 5.6%, P/S 1.9.

Ratios vs sector

Medians of Health care companies in the same region (stocks and REITs).

Lower P/E, P/B, P/S and EV/EBIT mean cheaper; higher yields, returns and margins mean more for the price. Negative multiples (losses) are left out of the medians.
MetricICLRSector medianvs median
P/E34.225.7 · n=2633% above
P/B1.73.6 · n=4554% below
P/S1.94.7 · n=4060% below
EV/EBIT25.022.6 · n=2810% above
Free-cash-flow yield5.6%3.8% · n=3949% above
Dividend yield0.00%0.19% · n=99100% below
Return on equity5.0%5.2% · n=56near the median
Return on invested capital5.9%6.5% · n=478% below
Gross margin23.4%70.2% · n=3967% below
Net debt / EBITDA2.392.08 · n=2515% above

Value factor: 69 of 100 within the peer group. Full score breakdown →

Sector peers

The largest companies of the same sector and region.

NOVNNovartis AG22.46.818.75.6%2.8%10/10
NVSNovartis AG22.36.818.75.6%2.4%10/10
AZNAstraZeneca PLC28.35.922.84.1%1.2%5/10
AZNAstraZeneca plc28.35.922.84.1%1.7%6/10
NVONovo Nordisk A/S11.86.210.34.9%4.6%7/10
SNYSanofi13.41.518.26.9%4.3%7/10
SANSanofi SA13.41.518.26.9%4.8%9/10
GSKGSK plc14.55.111.87.7%3.5%9/10
TEVATeva Pharmaceutical Industries Limited97.86.243.32.5%0.0%6/10
ALCAlcon AG37.51.729.34.7%0.5%5/10

Fiscal-year history

From annual SEC filings; each bar is a fiscal year, labelled by the year it ended.

Filings: U.S. SEC EDGAR · ratios computed by AI-Stock Invest from public filings and end-of-day prices · latest period 30 Sep 2026 · filed 27 Oct 2026